Inhibikase Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $13.4M | $10.8M | $7.6M | $5.3M | $10.5M | $7.2M | $4.2M | $3.1M |
| SG&A Expense | $7.7M | $7.4M | $5.6M | $5.9M | $5.2M | $5.7M | $1.6M | $2.0M |
| Operating Income | $-21.1M | $-17.8M | $-12.8M | $-10.8M | $-14.6M | $-12.9M | $-5.8M | $-5.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-19.6M | $-16.4M | $-11.9M | $-9.9M | $-13.7M | $-12.1M | $-5.8M | $-5.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.11 | $-0.10 | $-0.03 | $-0.03 | $-0.04 | $0.22 | $-0.04 | $-0.04 |
| EPS (Diluted) | $-0.11 | $-0.10 | $-0.03 | $-0.03 | $-0.04 | $0.22 | $-0.04 | $-0.04 |
| Shares Outstanding (Basic) | 174.6M | 172.3M | 360.2M | 360.0M | 358.1M | 94.8M | 142.1M | 120.6M |
| Shares Outstanding (Diluted) | 174.6M | 172.3M | 360.2M | 360.0M | 358.1M | 94.8M | 142.1M | 120.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |